Engage with experts and peers on all aspects of cardiac catheterization.
Richard A. Lange, MD, MBA and L. David Hillis, MD
The controversy over the use of genetic testing to guide antiplatelet therapy reminds us of a WWF (Worldwide Wrestling Federation) tag team match. What we agree upon (the match rules): Clopidogrel is a prodrug activated by several enzymes, including CYP2C19, and common genetic variations alter CYP2C19 activity. Here’s where the wrestling match begins: Are the CYP2C19 genetic…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: ACC, AHA, clopidogrel, CYP2C19, FDA, genetic testing, stent thrombosis
-
2 Recommendations
- |
-
3 Comments
L. David Hillis, MD and Richard A. Lange, MD, MBA
According to a recent meta-analysis of studies in patients undergoing PCI, rates of in-hospital mortality and emergency CABG for primary and non-primary PCI were similar at centers with and without on-site surgery. At least, that’s the story the press is spreading around. However, several caveats should be noted . . . 1. The study included…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: CABG, PCI
-
0 Recommendations
- |
-
5 Comments
